Nano cap Citius Pharmaceuticals (NASDAQ:CTXR) jumps 18% premarket on robust volume on the heels of FDA feedback that it could apply for Fast Track status for its induced mesenchymal stem cells to treat and reduce the severity of acute respiratory distress syndrome (ARDS) in COVID-19 patients.
The agency also provided requirements for chemistry, manufacturing and control (CMC) data for its proposed trials.
The company intends to follow-up on the regulator’s recommendations and with an IND application under the Coronavirus Treatment Acceleration Program.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.